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 Riboﬂavin as a bioorthogonal photocatalyst for the
activation of a PtIV prodrug†
Silvia Alonso-de Castro,a Emmanuel Ruggiero,a Ane Ruiz-de-Angulo,a
Elixabete Rezabal,bc Juan C. Mareque-Rivas,ad Xabier Lopez,ce Fernando Lo´pez-
Gallegoad and Luca Salassa *acde
Encouraging developments demonstrate that few transitionmetal and organometallic catalysts can operate
in a bioorthogonal fashion and promote non-natural chemistry in living systems by minimizing undesired
side reactions with cellular components. These catalytic processes have potential for applications in
medicinal chemistry and chemical biology. However, the stringent conditions of the cell environment
severely limit the number of accessible metal catalysts and exogenous reactions. Herein, we report an
unorthodox approach and a new type of bioorthogonal catalytic reaction, in which a metal complex is
an unconventional substrate and an exogenous biological molecule acts as a catalyst. In this reaction,
riboﬂavin photocatalytically converts a PtIV prodrug into cisplatin within the biological environment. Due
to the catalytic activity of riboﬂavin, cisplatin-like apoptosis is induced in cancer cells under extremely
low doses of light, potentially preventing systemic oﬀ-target reactions. Photocatalytic and bioorthogonal
turnover of PtIV into PtII species is an attractive strategy to amplify the antineoplastic action of metal-
based chemotherapeutics with spatio-temporal control.
Introduction
The combination of catalysis and bioorthogonality1–3 promises
to impact drug discovery and bioimaging by facilitating the
execution of non-natural chemical reactions in living systems.
Catalytic turnover can boost the eﬃciency of bioorthogonal
chemical reactions, unveiling new strategies for prodrug acti-
vation and uncaging of molecular probes.4–8
In this context, transition metal and organometallic catalysts
have opened new avenues for the advancement of bioorthogonal
catalysis in cells.5,9–16 In the studies carried out in the laborato-
ries of Meggers, Mascaren˜as, Unciti-Broceta, and Bradley, orga-
noruthenium and palladium catalysts were used to deprotect
pro-uorescent substrates and activate prodrugs in cancer cells
or in their compartments and surroundings.11–14,16 Rotello
devised biomimetic nanoenzymes for imaging and therapy by
encapsulating ruthenium and palladium catalysts into water-
soluble gold nanoparticles and controlling their catalytic
activity in HeLa cells through supramolecular chemistry.15 These
pioneering systems have exploited metal-based catalytic uncag-
ing of allylcarbamate- and propargyl-protected amines as viable
strategies for bioorthogonal catalysis; however, new biocom-
patible transformations are highly needed to further advance
this extremely challenging eld that is still in its infancy.
Herein, we described an original photocatalysis approach to
control the reactivity of transition metal complexes in a bio-
orthogonal fashion. In a new type of light-driven reaction, the
exogenous biological molecule riboavin (Rf) functions as
a bioorthogonal photocatalyst and a metal complex acts as an
unconventional substrate (Scheme 1).
This unusual catalyst/substrate pair relies on the photoredox
properties of Rf to enable the selective activation of a PtIV
Scheme 1 Transition-metal complex acting as a substrate and its
bioorthogonal activation by riboﬂavin that functions as
a photocatalyst.
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prodrug of cisplatin with exceptionally low doses of blue light
and induce apoptotic death in PC-3 human prostate cancer
cells.
Metal complexes are typically regarded as catalysts that
convert organic substrates into more valuable compounds;
however, to date, catalytic transformations of metal complexes
are practically unknown and represent a paradigm shi in
catalysis.17,18 Their development can expand the scope of bio-
orthogonal chemical reactions to inorganic substances and
metal-based prodrugs, fostering the creation of new inorganic
chemistry toolkits for biology and medicine.
Results and discussion
As part of our ongoing eﬀorts to design innovative light-
activation modes for anticancer platinum complexes,19 we
reasoned that Rf and its rich photochemistry would
facilitate the photoreduction of cis,cis,trans-[Pt(NH3)2
(Cl)2(O2CCH2CH2CO2)2]
2 (1) to cisplatin via light irradiation at
460 nm, a wavelength that is appropriate for use in biological
systems (Scheme 2). Complex 1 is a cisplatin prodrug suitable
for photochemotherapy because of its high dark stability in
aqueous solutions and negligible dark cytotoxicity in several
cancer cell lines such as prostate cancer PC-3 cells.20,21
Upon UVA light excitation (385 nm), 1 undergoes photo-
chemical activation. However, UVA light is of limited use in
therapy, and PtIV complexes such as 1 rarely display satisfactory
absorption features at wavelengths longer than 400 nm (Fig. 1a).
Rf is vitamin B2 and the precursor of biologically important
cofactors such as FMN and FAD, which are essential to humans
and animals due to their redox activity.22 The yellow-colored Rf
can absorb light with a wavelength as high as ca. 500 nm in
aqueous media with good extinction coeﬃcients (3446 > 10
4 M1
cm1)23 (Fig. 1a) and can promote a great variety of light-
induced reactions that depend on its 7,8-dimethyl-10-
alkylisoalloxazine fragment.22 Rf has been adopted as a photo-
catalyst in several organic reactions including the photooxida-
tion of benzyl alcohols and alkyl benzenes or the [2 + 2]
cycloaddition of styrene dienes and bis(arylenones).24–26
Photocatalytic activation of a PtIV prodrug by riboavin in
solution
Aer conrming that blue light had no direct eﬀects on 1
(Fig. S1–3†), we investigated the capability of Rf to photoactivate
the complex upon 460 nm excitation in MES buﬀer. Using low
excitation power density (2.5 mW cm2), 120 mM solutions of 1
were photolysed in the presence of Rf at various concentrations
(12–120 mM, Fig. S4–7†). The process was monitored via
1H NMR by the evolution of diagnostic peaks corresponding
to the Pt-bound (triplets) and free (singlet) succinate ligands
(Fig. 1b).
Sub-stoichiometric quantities of Rf were capable of causing
full conversion of 1 into its photoproducts under light excita-
tion, demonstrating that Rf did not act as a simple photosen-
sitizer but was indeed a photocatalyst. The eﬃciency of this
catalytic process was remarkable since 12 mM Rf converted
100% of 120 mM 1 in 5 minutes (light dose 0.75 J cm2). A Rf
concentration as low as 0.13 mM still photocatalysed the trans-
formation of 1 (120 mM); however, more than 2 hours were
required to achieve 27% of conversion (Fig. S8†). No reaction
between 1 and Rf occurred in the dark within 1 week (Fig. S9†).
Interestingly, photoconversion of 1 occurred in pure water (pH
5) or in phosphate buﬀer (PB, 100 mM, pH 5.5), but never
reached completion due to the poor photostability of Rf in these
media (vide infra). Thus, MES buﬀer plays a key role in the
catalytic process by preventing Rf from undergoing photode-
composition reactions.
To assess the rate law for the Rf-catalysed photoreduction of
1 to PtII species, we studied the reaction rate at diﬀerent
substrate concentrations (120 mM–1.92 mM, i.e. 2.4–38.4 mol
equiv. of 1 compared to Rf) in 18 mMMES buﬀer during 30 s of
irradiation at 298 K (Fig. S10†). The eﬀect of MES on the reac-
tion rate was evaluated in a separate set of experiments, in
which MES concentration was varied in the 3–20 mM range
(Fig. S11†). Results demonstrated that the rate of the reaction
linearly increased with the concentration of 1 and MES, corre-
sponding to a rst-order reaction for both species. Importantly,
the reaction showed a stronger dependency on the concentra-
tion of 1 than on the concentration of MES, suggesting that PtIV
reduction is the limiting step of the reaction.
Since our experiments employed a large excess of MES and
all the reaction steps were irreversible, the rate constant could
Scheme 2 Light-induced reduction of cis,cis,trans-[Pt(NH3)2(Cl)2-
(O2CCH2CH2CO2)2]
2 (1) promoted by riboﬂavin (Rf) in MES buﬀer.
Fig. 1 (a) Absorption spectrum of riboﬂavin (Rf) and cis,cis,trans-
[Pt(NH3)2(Cl)2(O2CCH2CH2CO2)2]
2 (1) in aqueous solution. (b) Rf-
catalysed photoreduction of 1 in the MES buﬀer (18 mM, pH 6)
monitored by 1H NMR. Spectra were obtained for a MES/D2O (9 : 1)
solution of 120 mM 1 and 50 mM Rf upon t¼ 0 s, 30 s, 1 min, and 2.5 min
of 460 nm light irradiation (2.5 mW cm2). 1H NMR signal labelling:
Pt–OCOCH2CH2CO2
, Pt–OCOCH2CH2CO2
, methyl groups of
Rf isoalloxazine ring, and free O2CCH2CH2CO2
.
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be described using the pseudo-rst-order model (ESI†). Using
50 mM Rf, we obtained a pseudo-rst-order reaction constant
(kobs ¼ 10.0  0.05  103 s1) that increased with the catalyst
concentration (Fig. S12 and S13†) and depended on the MES
concentration.
A turnover frequency (TOF) value of 0.22  0.06 s1 was
determined for the conversion of 1 (1.92 mM) by Rf (50 mM)
under light irradiation at 298 K in 18 mM MES buﬀer. Under
these reaction conditions, the maximum total turnover number
(TTN) value was 38 aer 3 minutes of light irradiation, and no
decomposition of the catalyst was observed by 1H NMR. The
Rf/1 catalyst/substrate pair achieved approx. 70–700 times
higher TOF compared to that of ruthenium(II) organometallic
catalysts, which catalytically converted NAD+ to NADH or
transformed O-allyl carbamates into their respective amines
under biologically relevant conditions and in cells.8,9 High TOF
is crucial for application in photochemotherapy since it guar-
antees rapid and suﬃcient conversion of 1 under short irradi-
ation time and low light dose conditions.
Mechanism of photocatalytic activation
Rf is extremely light sensitive, and its photochemical reactivity
strongly depends on the surrounding environment. Electron
transfer and proton-coupled reactions or singlet-oxygen gener-
ation take place upon light excitation of Rf, depending on the
availability of electron donors. In addition, light decomposes Rf
into several fragments through intramolecular reactions in
which the ribityl chain can be used as an electron source.27
Direct energy transfer from Rf to 1 can be ruled out since
there is no overlap between the emission band of Rf (lem ¼ 535
nm) and the absorption band of 1.
Hence, the sensitizing and catalytic capacity of Rf in MES
buﬀer reasonably relies on electron transfer processes triggered
by light. In the triplet excited state (3Rf*), Rf is a strong oxidant
(E ¼ 1.77 V)22 capable of eﬃciently extracting electrons from
the abundant MES molecules and generates the two-electron
reduced RfH2/RfH
 species (pKa  6) together with morpho-
lino radicals,28 which eventually evolve to the oxidized N-oxide
form of MES (Fig. S14†).29
Employing ferrioxalate actinometry,30 we determined the
photochemical quantum yield for Rf/1 (50 mM/1.0 mM, 18 mM
MES) to be 1.4  0.1 (Fig. S15 and S16†).
Yield values >1 are rather common in photoredox catalysis
where radical chain propagation cycles form part of the catalytic
mechanism.31
MES buﬀer dramatically improves Rf photostability by pre-
venting the isoalloxazine unit from reacting with the ribityl moiety
or with molecular oxygen. NMR and UV-vis spectra showed that
MES substantially preserved Rf from decomposition for over
30 min, whereas the catalyst was fully converted to the photo-
product lumichrome in water within 1 min of light irradiation and
then to 2,3-butanedione at longer irradiation times (Fig. S17–19†).32
The role of the buﬀer was conrmed using HEPES (18 mM,
pH 6), an analogue zwitterionic buﬀering agent (Fig. S20 and
S21†), in which Rf and 1 behaved similar to MES in terms of
photocatalytic activity.
The presence of sodium azide (singlet oxygen scavenger) in
water and PB also improved the eﬃciency of the photocatalytic
reaction of Rf with 1 (Fig. S22 and S23†). When added to the
MES buﬀer, sodium azide did not improve the eﬃciency of the
photocatalytic reaction of Rf with 1 (Fig. S24†) and excluded the
participation of 1O2 and other oxygen radicals playing major
roles in the catalytic mechanism. On the other hand, O2
partially deactivated Rf since under an inert Ar atmosphere, the
photoconversion of 1 was faster (Fig. S25†).
Importantly, complex 1 (1.8 mM) does not aﬀect the uo-
rescence lifetime of Rf in MES (Fig. S26 and S27†), indicating
that the active catalyst is not likely to be a Rf excited-state
species. Therefore, photooxidation of MES ultimately leads to
the formation of reduced (ground-state) RfH2/RfH
, whose low
redox potential (ca. 0.2 V)22 cannot directly promote the
reduction of 1 (0.9 V).33
However, as suggested by the density functional theory (DFT)
modelling (PBE0/def2-SVP) and in accordance with the results
obtained under an Ar atmosphere, 1 is capable of forming
adducts with either RfH2 (Fig. 2a) or RfH
 (Fig. S28–30†) via H-
bonding interactions between its succinate and amino ligands
and the isoalloxazine and ribityl groups of Rf. FMN and FAD
also photocatalyze the PtIV conversion of 1, displaying an eﬃ-
ciency comparable to that of Rf (Fig. S31–34†). FAD, however, is
somewhat less active, possibly due to steric constrains intro-
duced by its adenine moiety, which would disfavour H-bonding
between the complex and the avin.
Computed 1-RfH2 and 1-RfH
 adducts have the HOMO
localized on the Rf isoalloxazine rings, whereas LUMO and
LUMO+1 are s-antibonding orbitals of 1. Absorption of a second
photon and subsequent light-induced population of the disso-
ciative LUMO orbitals can trigger photoreduction and ligand
elimination reactions,34 ultimately promoting the formation of
cisplatin and other PtII species. However, at this stage, we cannot
exclude that these strong and specic interactions could
signicantly lower the redox potential of 1 and cause direct
reduction of the prodrug once the Rf-adducts are formed.35,36
Calculated binding energies for 1-RfH2 and 1-RfH
 adducts are
in the range of 52–69 kcal mol1, indicating that these transient
species are strongly stabilized and may bestow unique selectivity
to the Rf/1 catalyst/substrate pair (vide infra).
A pH-dependency prole for the photoreaction at xed light-
irradiation time (2.5 min) showed that complete photo-
conversion of 1 occured above pH 6 in MES, whereas at lower
pHs, the photocatalysis was less eﬃcient (Fig S35†). This
nding is in agreement with the prevalence of the RfH2/RfH

forms of reduced Rf at pH values higher than 6.22
On the basis of the described evidence, we propose a tenta-
tive photocatalytic mechanism for the Rf/1 catalyst/substrate
pair, as shown in Fig. 2b; however, further investigations will
be needed for the complete elucidation of this mechanism.
Photocatalysis in the biological environment
To test the potential of Rf photocatalyst as a bioorthogonal tool
for photochemotherapy, we studied the activation of 1 by Rf in
a cell culture medium and its eﬀects in PC-3 cancer cells (in
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 4619–4625 | 4621




























































































which 1 has no dark toxicity). At rst, photocatalysis experi-
ments and controls (Fig. S36 and S37†) were performed in
Ham's F-12Kmedium supplemented with fetal bovine serum, in
which biological components such as growth factors, anti-
bodies, amino acids, vitamins, and inorganic salts were present
at concentrations ranging from mM to mM.
1H NMR data showed that 3 min of blue light irradiation
(light dose 1.08 J cm2) can fully convert 1.92 mM 1 to PtII
species in the presence of 50 mM Rf and 3 mMMES, without any
signicant side reaction aﬀecting either the medium compo-
nents or the catalyst (Fig. S38†). Under these conditions, the
TOF and TTN for the Rf catalyst were as good as those in pure
MES buﬀer solutions, indicating that the catalytic process was
bioorthogonal in cell culture medium.
The antiproliferative activity of Rf/1 against PC-3 cancer cells
was investigated in the dark and under 460 nm light irradiation
by co-administering the catalyst/substrate pair at the molar
ratio of 1 : 4 and using three diﬀerent concentrations of
complex (40, 80, and 120 mM). In our cell experiments, Rf
prevalently activated 1 in the extracellular space since we per-
formed light irradiation aer a short pre-incubation period and
replaced culture medium aer 6 h. Once photocatalytically
generated, PtII species could be internalized by cells and exerted
their antiproliferative action. MES is well tolerated by cells
(Fig. S39†) and was hence employed during cell viability assays
as an electron donor. Under these conditions, a short light
irradiation period (1 min) and an extremely low light dose (0.36
J cm2) were suﬃcient for the full photoconversion of 1 by Rf
(Fig. S40 and S41†). In the absence of MES, the photoactivation
of 1 still took place, although less eﬃciently (Fig. S42†), likely
because other biological components of the medium acted as
electron donors. Against PC-3 cells, the Rf/1 catalyst/substrate
pair displayed dose-dependent light-induced toxicity compa-
rable to that of cisplatin in the dark. Remarkably, 120 mM 1 and
30 mM Rf induced a 55  5% reduction in cell biomass under
light irradiation, against a 65  5% reduction caused by
cisplatin at the same concentration. Control experiments indi-
cated that Rf/1 did not reduce viability of the PC-3 cells when
kept in the dark neither did any of the components when
individually irradiated (Fig. 3a).
The antiproliferative action of Rf-activated 1 is associated
with the formation of cisplatin as one of the major cytotoxic
photoproducts. Initial evidence was gathered from binding
experiments with the RNA and DNA base model 50-guanosine
Fig. 2 Proposedmechanism for the photocatalytic activation of 1 by Rf. (a) Computed structure and frontier molecular orbitals (DFT:PBE0/def2-
SVP) of a selected 1-RfH2 adduct. Intermolecular H-bonds in 1-RfH2 are highlighted withmagenta lines (top). Isodensity surfaces are plotted with
the isovalue of 0.02 e bohr3. Atoms color code: Pt grey, Cl green, O red, N blue, C pale brown (1) or yellow (Rf), H white. (b) Rf absorbs 460 nm
photons to generate the triplet excited state (3Rf*), which oxidizes two MES molecules to give the reduced species RfH2/RfH
. Next, complex 1
forms stable adducts with either RfH2 (shown in Fig. 2a) or RfH
 and undergoes photoreduction and elimination reactions upon absorption of
more photons, liberating cytotoxic PtII species and regenerating the Rf catalyst.
4622 | Chem. Sci., 2017, 8, 4619–4625 This journal is © The Royal Society of Chemistry 2017




























































































monophosphate (GMP). 1H NMR showed that irradiated Rf/1
solutions incubated with GMP (0–24 h) presented the diagnostic
peak, corresponding to the cisplatin mono-GMP–PtII adduct
(Fig. S43 and S44†).37 When incubated with pET28b as a model
of double-stranded circular DNA (24 h, MES 1.5 mM, pH 6),
light-activated Rf/1 (2.5 : 10 mM) inhibited the polymerase chain
reactions (PCR). Thus, thirty seconds of light irradiation was
suﬃcient to stop DNA amplication and reach a PCR inhibition
level comparable to that of cisplatin (10 mM), hence conrming
the capacity of this biorthogonal system to produce DNA-
targeting species (Fig. S45†).38,39
Fluorescence microscopy results on PC-3 cells treated with
either irradiated Rf/1 (30 : 120 mM) or cisplatin (120 mM) were in
agreement with this scenario (Fig. 3b and S46†). In both cases,
images obtained aer 48 h of incubation showed increased
percentage of apoptotic versus viable cells, together with
changes in the cell morphology that are characteristic of
apoptosis, i.e. cell shrinkage and rounding. Non-treated cells
and cells treated with Rf/1 in the dark included as controls did
not induce appreciable cell death.
Consistently, ow cytometry results conrmed that PC-3
cells exposed to the Rf/1 mixture and light (30 : 120 mM) died
through apoptosis 48 hours aer irradiation. Cisplatin induced
comparable levels of apoptosis under the same conditions.
Double staining with Pacic Blue™ Annexin V/SYTOX®
allowed to diﬀerentiate between early-stage and late-stage
apoptosis. Upon treatment with irradiated Rf/1, the
percentage of early apoptotic cells was 16.7  2.8% against 19.9
Fig. 3 Antiproliferative activity in human prostate cancer PC-3 cells. (a) Percentage cell viability of PC-3 cells following treatment with Rf, 1, Rf/1
and cisplatin with and/or without light activation (460 nm, 0.36 J cm2). (b) Fluorescencemicroscopy images showing the eﬀects of Rf/1 on PC-
3 cells upon light irradiation. (A and B) Untreated PC-3 cells, (C and D) Rf/1 (30 : 120 mM) in the dark, (E and F) Rf/1 (30 : 120 mM) activated by
460 nm light and (G and H) cisplatin (120 mM) in the dark. Top row: cell nuclei (green); bottom row: apoptotic cells (red). (c) Quantiﬁcation of early
apoptotic PC-3 cells (Annexin V+/SYTOX) treated by Rf (30 mM), Rf/1 (30 : 120 mM) and cisplatin (120 mM) with and/or without light activation.
Cell viability and ﬂow cytometry data are presented as mean  SEM of at least three independent measurements. ***P < 0.001, **P < 0.01, ns ¼
non-signiﬁcant by two-way ANOVA followed by Bonferroni's test (a) or by one-way ANOVA followed by Tukey's test (c).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 4619–4625 | 4623




























































































 1.3% obtained for cisplatin. Rf, 1, and Rf/1 in the dark
exhibited no signicant population of the cells in either stage of
apoptosis aer 48 h of incubation (Fig. 3c).
Conclusions
In summary, we described the rst photocatalytic activation of
a metal-based prodrug in solution and in a biological environ-
ment. Co-administration of the Rf/1 as a catalyst/substrate
couple enabled photoconversion of 1 into biologically active
species by light irradiation at 460 nm, a wavelength that is
ineﬀective when directly applied to the prodrug. In addition, the
Rf/1 prodrug activation strategy induced an anticancer activity
comparable to that of cisplatin with light doses as low as 0.36 J
cm2; that is ca. 15–35 times lower than what is typically used
for UVA and blue light activation of analogue platinum
complexes.40,41
The photocatalytic turnover of PtIV into PtII species is an
attractive prospect to amplify the antineoplastic action of metal-
based prodrugs in a locoregional manner. This is particularly
relevant for platinum anticancer agents, which have some of the
poorest absorption properties amongst photoactivatable metal
complexes but are widely tested in preclinical work and nearly
indispensable in clinical practice.
In principle, photocatalysis can help expand the therapeutic
potential of platinum prodrugs. Eﬃcient light activation of PtIV
complexes through catalysis may help localize the cytotoxic
eﬀects of Pt drugs, increase their dosing at the tumour target,
and reduce their systemic toxicity. Rf (vitamin B2) is a highly
biocompatible molecule, and its capacity to function in a bio-
orthogonal fashion may serve to enhance the selectivity of
metal-based drugs by minimizing side reactions.
Experimental section
Methods
NMR, UV-vis, and uorescence characterization of light-
irradiated Rf/1 and controls, PCR and microscopy data, photo-
chemical quantum yield by actinometry, setup for cell work
under light irradiation, computational methodology and
instrumentation details are described in the ESI.†
Light-irradiation experiments in solution
Photocatalysis studies on Rf/1 were performed under diﬀerent
solution conditions (buﬀers, cell culture medium, and in the
presence of co-reactants). All the reactions were carried out in air
at 298 K and pH 6, employing an LED light source (lexc¼ 460 nm,
2.5 mW cm2). Reaction kinetics, rate laws of the reaction, turn-
over frequency (TOF), and total turnover number (TTN) were
calculated by varying both the reactants and catalyst concentra-
tion and quantifying the amount of photoconverted 1 via 1HNMR.
Cell viability studies
The antiproliferative activity of Rf/1 was determined in human
prostate cancer cells PC-3 (ATCC) in the dark and under light
irradiation by co-administering Rf and 1 at the xed molar ratio
(1 : 4) and using three diﬀerent concentrations (Rf/1 : 10/40 mM,
20/80 mM, and 30/120 mM). MES was employed in all the cell
experiments at the nal concentration of 2 mM. PC-3 cells were
seeded 24 h before the experiment in 96-well plates with
a density of 4000 cells per well and grown under standard
conditions (Ham's F-12K medium supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin at 37 C, 5% CO2
and 90% humidity). Stock solutions of Rf/1 were added and
incubated with cells for 1 h, light irradiated for 1 min at 460 nm
(light dose 0.36 J cm2), and then incubated for other 6 h.
Finally, cells were washed in fresh medium and grown for other
42 h. The sulforhodamine B (SRB) colorimetric assay was used
for cell density determination. As controls, Rf and 1 were tested
under identical conditions, whereas parallel experiments were
performed with Rf/1 and cisplatin kept in the dark. A home-
made LED plate was employed to irradiate cells in 96-well
plates (Fig. S47†).
Fluorescence microscopy assays
PC-3 cells exposed to 30 : 120 mM Rf/1 were viewed using a Zeiss
Axio Observer wide eld uorescence microscope (Carl Zeiss).
Cells were plated in an ibidi m-Slide 0.4 (13500 PC-3 cells/
channel) and allowed to adhere overnight before they were
treated with Rf/1, as described for cell viability experiments
(2 mM MES, 6 h of treatment plus 42 h incubation). Analysis of
cellular morphological alteration was performed using a cell-
permeable green uorescent dye from the Live and Dead Cell
Staining Kit (Abcam) for cell nuclei (green channel) and
SYTOX® AADvanced™ (Invitrogen™) for dead cells (red
channel). Cells were stained following commercial protocols
and using binding or 10 mM PBS buﬀer at the end of the
incubation period (48 h). Images were acquired using a Plan
Apochromat 20 objective and a multi-band pass Colibri lter
to obtain the uorescence emission signals. Control experi-
ments in the dark (no light irradiation) were performed on
untreated cells and on the cells exposed to 30 : 120 mM Rf/1 or
120 mM cisplatin.
Flow cytometry analysis
PC-3 cells were seeded in 96-well plates (2000 cells per well) and
treated with Rf/1 (30 : 120 mM) and MES (2 mM) as described
above. Aer 48 hours of incubation, 7 wells for each sample
were pooled into cytometer tubes; cells were washed with
10 mM PBS and stained using 100 mL per tube of the Pacic
Blue™ Annexin V/SYTOX® AADvanced™ ow cytometry kit
(Invitrogen™). Early and late apoptosis were measured using
a FACS Canto II (BD Biosciences) and results were analysed
using the FlowJo, LCC soware. The PC-3 population was elec-
tronically gated based on the forward and side scatter param-
eters and the non-single events le out based on the forward
area and height scatter parameters. Inside this nal population,
live cells were gated as negative for both dyes; early apoptotic
cells were dened as Pacic Blue-Annexin V positive cells and
SYTOX® negative, whereas late apoptotic cells were gated as
double positive for both dyes. Non-labelled and singly labelled
samples were included as a control and as compensation
4624 | Chem. Sci., 2017, 8, 4619–4625 This journal is © The Royal Society of Chemistry 2017




























































































samples, respectively. Experiments were repeated three times.
In addition to untreated cells, control experiments included
cells treated with 30 : 120 mM Rf/1 and 120 mM cisplatin in the
dark (no light irradiation) and light-irradiated Rf and 1 alone.
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